RecruitingNCT04731831

Characterization of Immunogenicity of TNF Inhibitors in Arthritis Patients With Poorer Treatment Response.

Characterization of Immunogenicity of Tumor Necrosis Factor Inhibitors in Arthritis Patients With Poorer Treatment Response Due to Gender, Obesity and Smoking Status.

Sponsor

Aalborg University Hospital

Enrollment

120 participants

Start Date

Aug 1, 2020

Study Type

OBSERVATIONAL

Conditions

Arthritis, Rheumatoid Arthritis, Psoriatic Spondylitis, Ankylosing

Summary

The aim of the study is to explore whether the influence of gender, tobacco smoking and obesity on treatment response in tumor necrosis factor inhibitors (TNFIs) can be explained by high degree of inflammation, human leucocyte antigen (HLA) type, autoantibodies, TNF and TNFI concentration and presence of ADA.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study looks at why some people with inflammatory arthritis stop responding well to certain biologic medications over time. Specifically, it studies whether the body develops antibodies against the drug (called immunogenicity), which can make the drug less effective. **You may be eligible if...** - You are over 18 years old - You have been diagnosed with rheumatoid arthritis (RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) - You are about to start treatment with infliximab (Remicade) or adalimumab (Humira) - You may also be taking other standard arthritis medications or low-dose steroids **You may NOT be eligible if...** - You do not have one of the listed arthritis diagnoses - You are currently starting any other biologic medication at the time of enrollment Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.